,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,2063,1,2,,85209093,3510,Active,,,,,Ligands of peptide (Class A) GPCRs,Other,,
1,2660,1,1,,90340785,3510,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
2,2666,1,1,,90340785,3510,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
3,2667,1,1,,90340785,3510,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
4,2668,1,1,,90340785,3510,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
5,4328,4,6,,124963825,3510,Unspecified,,,1.0,Ki,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,Confirmatory,2258903.0,
6,4702,4,6,,124963825,3510,Unspecified,,,1.0,Ki,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,Confirmatory,2258903.0,
7,4765,4,11,,124963825,3510,Unspecified,112817.0,25187.0,1.0,Ki,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Confirmatory,2258903.0,
8,4875,4,6,,124963825,3510,Unspecified,,,1.0,Ki,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,Confirmatory,2258903.0,
9,5290,4,6,,124963825,3510,Unspecified,,,1.0,Ki,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,Confirmatory,2258903.0,
10,5881,4,9,,124963825,3510,Active,,,10.0,Ki,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,Confirmatory,2362270.0,
11,5882,7,3,,124963825,3510,Active,,,0.00059,Ki,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,Confirmatory,2362270.0,
12,5883,4,7,,124963825,3510,Unspecified,,,1.0,Ki,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,Confirmatory,2362270.0,
13,5884,7,1,,124963825,3510,Active,,,0.0039,Ki,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Confirmatory,10585211.0,
14,5886,7,2,,124963825,3510,Active,,,0.00172,Ki,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Confirmatory,1312602.0,
15,5887,7,3,,124963825,3510,Active,,,0.00078,Ki,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,Confirmatory,8246239.0,
16,5890,7,2,,124963825,3510,Active,,,0.0021,Ki,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,Confirmatory,1479589.0,
17,5891,7,1,,124963825,3510,Active,,,0.0006,Ki,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,Confirmatory,9464362.0,
18,5893,7,1,,124963825,3510,Active,,,0.00035,Ki,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Confirmatory,9513601.0,
19,5896,7,1,,124963825,3510,Active,,,0.00035,Ki,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,Confirmatory,9341912.0,
20,5898,7,1,,124963825,3510,Active,,,0.00162,Ki,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Confirmatory,2258903.0,
21,5910,4,1,,124963825,3510,Unspecified,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,Other,1548679.0,
22,5933,5,5,,124963825,3510,Active,,,2.51e-05,Kd,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,Confirmatory,2362270.0,
23,5963,3,7,,124963825,3510,Active,,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Other,9341912.0,
24,5964,7,2,,124963825,3510,Active,,,0.007940000000000001,Kd,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Confirmatory,2342053.0,
25,5976,8,1,,124963825,3510,Unspecified,,,7000000.0,ED50,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Confirmatory,10585211.0,
26,5980,7,4,,124963825,3510,Active,,,0.0021,Ki,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Confirmatory,8230119.0,
27,5982,5,7,,124963825,3510,Active,,,0.01585,Kd,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Confirmatory,,
28,6011,3,6,,124963825,3510,Unspecified,,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,Other,2342053.0,
29,6015,3,7,,124963825,3510,Unspecified,,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Other,,
30,6026,7,3,,124963825,3510,Active,,,0.000126,Kd,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Confirmatory,2342053.0,
31,6027,7,3,,124963825,3510,Active,,,2e-05,Kd,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Confirmatory,2342053.0,
32,6030,5,5,,124963825,3510,Active,,,7.94e-05,Kd,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Confirmatory,,
33,6031,5,5,,124963825,3510,Active,,,0.000126,Kd,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Confirmatory,,
34,6056,6,8,,124963825,3510,Unspecified,1168223.0,79246.0,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Other,8496941.0,
35,6056,6,8,,124963825,3510,Unspecified,81868595.0,58963.0,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Other,8496941.0,
36,6058,9,1,,124963825,3510,Active,,,1.76,IC50,Binding affinity towards 5-HT3 receptor in rat was evaluated,Confirmatory,11755351.0,
37,6084,6,3,,124963825,3510,Unspecified,,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,Other,2362271.0,
38,6089,6,4,,124963825,3510,Unspecified,,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,Other,2362270.0,
39,6129,3,11,,124963825,3510,Active,1168223.0,79246.0,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Other,10229626.0,
40,6129,3,11,,124963825,3510,Active,81868595.0,58963.0,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Other,10229626.0,
41,6132,8,5,,124963825,3510,Active,1168223.0,79246.0,0.00035,Ki,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Confirmatory,10229626.0,
42,6132,8,5,,124963825,3510,Active,81868595.0,58963.0,0.00035,Ki,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Confirmatory,10229626.0,
43,6136,7,1,,124963825,3510,Active,,,0.0021,Ki,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,Confirmatory,8496941.0,
44,6137,7,1,,124963825,3510,Active,,,0.0005,Ki,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,Confirmatory,9685241.0,
45,6159,10,5,,124963825,3510,Unspecified,6224984.0,100135548.0,1.0,IC50,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Confirmatory,11755351.0,
46,6214,3,8,,124963825,3510,Inactive,,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Other,,
47,6244,7,2,,124963825,3510,Unspecified,,,1.0,Ki,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Confirmatory,10585211.0,
48,6255,3,10,,124963825,3510,Unspecified,2494928.0,25324.0,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Other,9599243.0,
49,6284,5,1,,124963825,3510,Active,,,0.000589,Ki,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Confirmatory,2342053.0,
50,6285,4,1,,124963825,3510,Active,,,0.00912,Ki,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,Confirmatory,2342053.0,
51,6291,4,1,,124963825,3510,Active,1168223.0,79246.0,0.000251,Ki,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Confirmatory,,
52,6291,4,1,,124963825,3510,Active,81868595.0,58963.0,0.000251,Ki,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Confirmatory,,
53,6292,4,1,,124963825,3510,Active,,,0.002,Ki,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,Confirmatory,9046349.0,
54,6298,5,1,,124963825,3510,Active,1168223.0,79246.0,0.00162,Ki,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Confirmatory,2258903.0,
55,6298,5,1,,124963825,3510,Active,81868595.0,58963.0,0.00162,Ki,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Confirmatory,2258903.0,
56,6310,5,1,,124963825,3510,Active,,,0.000794,Ki,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,Confirmatory,8410977.0,
57,6322,6,5,,124963825,3510,Unspecified,,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,Other,,
58,6344,7,4,,124963825,3510,Active,,,0.024,Ki,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Confirmatory,11212100.0,
59,14399,3,4,,124963825,3510,Unspecified,,,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Other,10377231.0,
60,14400,3,3,,124963825,3510,Unspecified,,,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",Other,10377231.0,
61,14401,3,4,,124963825,3510,Unspecified,,,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Other,10377231.0,
62,26326,3,4,,124963825,3510,Unspecified,,,,,pKa value was determined,Other,,
63,61534,9,1,,124963825,3510,Unspecified,,,1.0,IC50,Binding affinity towards D2 receptor in rat was evaluated,Confirmatory,11755351.0,
64,71931,3,3,,124963825,3510,Unspecified,,,,,"Antiemetic activity (intravenous administration) against cisplatin-induced emesis in ferret, as the dose required to increase latency to first emetic bout by 100%",Other,1312602.0,
65,72053,3,3,,124963825,3510,Unspecified,,,,,Antiemetic potency against cisplatin-induced emetic latency period in ferret after intravenous administration,Other,1548679.0,
66,72054,3,3,,124963825,3510,Unspecified,,,,,Antiemetic potency was tested against cisplatin-induced emetic latency period in ferret after oral administration,Other,1548679.0,
67,72056,6,2,,124963825,3510,Unspecified,,,,,"Antiemetic activity (intravenous administration) against cisplatin-induced emesis in ferret, as the dose required to reduce emetic episodes to 50% of control value",Other,1312602.0,
68,72057,6,2,,124963825,3510,Unspecified,,,,,"Antiemetic activity (oral administration) against cisplatin-induced emesis in ferret, as the dose required to increase latency to first emetic bout by 50%",Other,1312602.0,
69,72058,6,2,,124963825,3510,Unspecified,,,,,"Antiemetic activity (oral administration) against cisplatin-induced emesis in ferret, as the dose required to reduce emetic episodes to 50% of control value",Other,1312602.0,
70,72060,6,2,,124963825,3510,Unspecified,,,,,Antiemetic potency was tested against cisplatin-induced emetic episodes in ferret after oral administration,Other,1548679.0,
71,79521,5,2,,124963825,3510,Active,,,0.0006309999999999999,Kd,Single-point analysis using 5(10e-9) M concentration of the antagonist (pA2= -log([B]/concentration ratio-1); [B] =concentration of the antagonist).,Confirmatory,10585211.0,
72,82355,5,6,,124963825,3510,Active,7531135.0,3757.0,3.73,IC50,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Confirmatory,12190308.0,
73,112440,6,2,,124963825,3510,Unspecified,,,,,"Inhibitory activity against 5-HT evoked diarrhea in mice, sc",Other,9685241.0,
74,122488,3,3,,124963825,3510,Unspecified,,,,,Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 0.3 mg/kg,Other,9685241.0,
75,122489,3,3,,124963825,3510,Unspecified,,,,,Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 1 mg/kg,Other,9685241.0,
76,122491,3,3,,124963825,3510,Unspecified,,,,,Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 3 mg/kg,Other,9685241.0,
77,122492,5,2,,124963825,3510,Unspecified,,,,,Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 30 mg/kg,Other,9685241.0,
78,143665,4,6,,124963825,3510,Active,,,0.0028,IC50,Quantitative effect on the [14C]guanidinium accumulation in NG 108-15 cells.,Confirmatory,10229626.0,
79,145856,8,4,,124963825,3510,Inconclusive,,,,,In vitro Binding affinity towards alpha-1-beta-1-gamma-delta nAChR was determined; not done,Other,11212100.0,
80,145991,7,2,,124963825,3510,Unspecified,,,67.0,Ki,In vitro Binding affinity towards alpha-3 (PC12) nAChR was determined,Confirmatory,11212100.0,
81,146640,7,2,,124963825,3510,Active,,,38.0,Ki,In vitro Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 was determined,Confirmatory,11212100.0,
82,146789,7,2,,124963825,3510,Unspecified,,,10.0,Ki,In vitro Binding affinity towards alpha-7 nAChR was determined,Confirmatory,11212100.0,
83,174946,3,4,,124963825,3510,Unspecified,,,,,"Time required to achieve 50% recovery of Bezold-Jarisch reflex in 9 rats at a dose of 6 ug/kg, iv",Other,,
84,177157,6,2,,124963825,3510,Unspecified,,,,,In vivo effective dose against Bezold-Jarisch reflex evoked by 5-HT in urethane-anesthetized rats,Other,9046349.0,
85,177426,6,2,,124963825,3510,Unspecified,,,,,Compound was evaluated for the inhibition of 5-HT induced bradycardia [Benzold-Jarisch (BJ) reflex test] in rats at 5 min,Other,1479589.0,
86,178008,6,2,,124963825,3510,Unspecified,,,,,Effective dose causing reduction of serotonin effect at 5 min administered iv in Bezold-Jarisch reflex test,Other,8230119.0,
87,178568,6,2,,124963825,3510,Unspecified,,,,,Effective dose required to inhibit 5-HT- mediated bradycardia in rat after intravenous administration,Other,2258903.0,
88,178575,6,2,,124963825,3510,Unspecified,,,,,Effective dose required to reduce von benzold jarisch reflex response to 5-HT was determined; Value ranges from 10-30 ug/Kg,Other,2258903.0,
89,179597,6,8,,124963825,3510,Unspecified,1168223.0,79246.0,,,Inhibition of the Bezold Jarisch reflex evoked by 30 ug/Kg of 5-HT.,Other,9341912.0,
90,179597,6,8,,124963825,3510,Unspecified,81868595.0,58963.0,,,Inhibition of the Bezold Jarisch reflex evoked by 30 ug/Kg of 5-HT.,Other,9341912.0,
91,179602,5,3,,124963825,3510,Unspecified,,,,,Antagonistic activity towards serotonin 5-HT3 receptor was evaluated by inhibition of 5-HT evoked reflexes in rat on intravenous administration,Other,,
92,180190,6,8,,124963825,3510,Unspecified,1168223.0,79246.0,,,The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered intravenously,Other,3625701.0,
93,180190,6,8,,124963825,3510,Unspecified,81868595.0,58963.0,,,The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered intravenously,Other,3625701.0,
94,180191,6,8,,124963825,3510,Unspecified,1168223.0,79246.0,,,The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered orally,Other,3625701.0,
95,180191,6,8,,124963825,3510,Unspecified,81868595.0,58963.0,,,The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered orally,Other,3625701.0,
96,182524,4,3,,124963825,3510,Unspecified,1168223.0,79246.0,,,Inhibition of the von Bezold-Jarisch reflex bradycardia induced by an iv bolus injection of 5-HT,Other,,
97,182524,4,3,,124963825,3510,Unspecified,81868595.0,58963.0,,,Inhibition of the von Bezold-Jarisch reflex bradycardia induced by an iv bolus injection of 5-HT,Other,,
98,182801,5,3,,124963825,3510,Unspecified,,,,,Dose required for inhibition of bradycardia induced by a submaximal dose (iv) of 5-HT in 9 rats,Other,,
99,183110,6,2,,124963825,3510,Unspecified,,,,,Inhibition of wrap-restraint stress-induced colonic propulsion measured by the time required to expel a teflon ball inserted 3 cm into the rat colon,Other,8230119.0,
100,183114,6,2,,124963825,3510,Unspecified,,,,,Inhibitory dose against 5-HT-Evoked Bezold-Jarisch (B-J) reflex in rats,Other,9685241.0,
101,183117,6,2,,124963825,3510,Unspecified,,,,,Inhibitory dose causing inhibition of increase in 5-HT induced defecation by sc administration 1 to 10 mg/kg,Other,8230119.0,
102,183119,6,2,,124963825,3510,Unspecified,,,,,Inhibitory dose causing inhibition of increase in castor oil induced diarrhea by oral administration at 1 ml/rat,Other,8230119.0,
103,183120,6,2,,124963825,3510,Unspecified,,,,,Inhibitory dose causing inhibition of increase in thyrotropin-releasing hormone (TRH) induced defecation by sc administration at 1 mg/kg,Other,8230119.0,
104,183121,6,2,,124963825,3510,Unspecified,,,,,Inhibitory dose causing inhibition of restraint stress induced defecation by oral administration,Other,8230119.0,
105,183143,6,2,,124963825,3510,Unspecified,,,,,Potency to inhibit bradycardiac effect measured by Von Bezold-Jarisch assay in 11 anesthetized rats,Other,8410977.0,
106,183155,4,11,,124963825,3510,Unspecified,1168223.0,79246.0,,,Antagonist activity (100 mg/Kg) for the Bezold Jarisch reflex evoked by 30(mg/Kg) of 5-HT in ethylurethane anesthetized rats (i.v.),Other,9341912.0,
107,183155,4,11,,124963825,3510,Unspecified,81868595.0,58963.0,,,Antagonist activity (100 mg/Kg) for the Bezold Jarisch reflex evoked by 30(mg/Kg) of 5-HT in ethylurethane anesthetized rats (i.v.),Other,9341912.0,
108,185593,3,4,,124963825,3510,Unspecified,,,,,"Percent maximum inhibition against Bezold-Jarisch reflex in 9 rats at a dose of 6 ug/kg, iv",Other,,
109,185962,3,4,,124963825,3510,Unspecified,,,,,Percentage inhibition von benzold jarisch reflex in rats when the compound was administered at dose of 100 ug/Kg 1 hr postadministration,Other,2258903.0,
110,229404,3,11,,124963825,3510,Unspecified,1168223.0,79246.0,,,Selectivity ratio of peroral vs intravenous delivery,Other,3625701.0,
111,229404,3,11,,124963825,3510,Unspecified,81868595.0,58963.0,,,Selectivity ratio of peroral vs intravenous delivery,Other,3625701.0,
112,239587,8,5,,124963825,3510,Active,1168223.0,79246.0,0.00035,Ki,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortical membrane,Confirmatory,15887964.0,
113,239587,8,5,,124963825,3510,Active,81868595.0,58963.0,0.00035,Ki,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortical membrane,Confirmatory,15887964.0,
114,243151,7,2,,124963825,3510,Active,,,3.71535,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
115,243189,7,4,,124963825,3510,Active,7531135.0,3757.0,3.80189,IC50,Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel),Confirmatory,15745831.0,
116,295453,3,11,,124963825,3510,Unspecified,24211440.0,100135547.0,,,Agonist activity at 5HT3 receptor in Hartley guinea-pig ileum assessed as muscle contraction,Other,17391967.0,
117,295454,3,11,,124963825,3510,Unspecified,24211440.0,100135547.0,,,Antagonist activity at 5HT3 receptor in Hartley guinea-pig ileum assessed as effect on 5-hydroxytryptamine-induced muscle contraction,Other,17391967.0,
118,295455,3,11,,124963825,3510,Inactive,24211440.0,100135547.0,,,Intrinsic activity at 5HT3 receptor in Hartley guinea-pig ileum assessed as muscle contraction at 0.1 mM relative to 5-hydroxytryptamine,Other,17391967.0,
119,311524,4,3,,124963825,3510,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
120,373867,6,3,,124963825,3510,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
121,420668,8,5,,124963825,3510,Active,7531135.0,3757.0,3.80189,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
122,420669,3,4,,124963825,3510,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
123,425652,7,2,,124963825,3510,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
124,425653,7,2,,124963825,3510,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
125,444050,7,1,,124963825,3510,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
126,444051,6,2,,124963825,3510,Unspecified,,,,,Total clearance in human,Other,20070106.0,
127,444052,6,2,,124963825,3510,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
128,444053,6,2,,124963825,3510,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
129,444054,6,1,,124963825,3510,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
130,444055,3,3,,124963825,3510,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
131,444056,3,3,,124963825,3510,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
132,444057,3,3,,124963825,3510,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
133,444058,6,2,,124963825,3510,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
134,461556,7,5,,124963825,3510,Active,1168222.0,3359.0,0.00145,Ki,Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting,Confirmatory,20146481.0,
135,463106,1,2,,90340785,3510,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
136,476929,3,3,,124963825,3510,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
137,485295,1,2,,90340785,3510,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
138,485297,1,1,,90340785,3510,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
139,485298,1,1,,90340785,3510,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
140,485313,1,2,,90340785,3510,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
141,485342,1,2,,90340785,3510,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
142,485345,1,2,,90340785,3510,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
143,485366,1,2,,90340785,3510,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
144,485368,1,2,,90340785,3510,Inconclusive,72386991.0,3656265.0,8.4921,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
145,488772,1,1,,90340785,3510,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
146,488773,1,2,,90340785,3510,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
147,488816,1,1,,90340785,3510,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
148,488837,1,1,,90340785,3510,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
149,488949,1,2,,90340785,3510,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
150,488953,1,1,,90340785,3510,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
151,488978,1,1,,90340785,3510,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
152,488981,1,1,,90340785,3510,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
153,488982,1,1,,90340785,3510,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
154,488983,1,1,,90340785,3510,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
155,493017,1,1,,103858514,3510,Unspecified,,3762.0,,,Wombat Data for BeliefDocking,Other,12190308.0,
156,493106,1,1,,90340785,3510,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
157,493107,1,1,,90340785,3510,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
158,493153,1,1,,90340785,3510,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
159,493153,1,1,,90340785,3510,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
160,493164,1,2,,90340785,3510,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
161,493164,1,2,,90340785,3510,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
162,493164,1,2,,90340785,3510,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
163,504327,1,1,,90340785,3510,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
164,504332,1,1,,90340785,3510,Inconclusive,168985070.0,,39.8107,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
165,504536,1,1,,90340785,3510,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
166,504547,1,1,,90340785,3510,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
167,504548,1,2,,90340785,3510,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
168,504810,1,2,,90340785,3510,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
169,504812,1,2,,90340785,3510,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
170,504836,1,2,,90340785,3510,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
171,504845,1,1,,90340785,3510,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
172,504847,1,1,,90340785,3510,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
173,504865,1,1,,90340785,3510,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
174,537659,6,2,,124963825,3510,Active,,,0.00398,Ki,Binding affinity to 5HT3A receptor,Confirmatory,20724042.0,
175,537660,1,3,,124963825,3510,Unspecified,,,,,Chemical stability of the compound assessed as half life,Other,20724042.0,
176,539464,4,2,,124963825,3510,Unspecified,,,,,Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis,Other,21055935.0,
177,540209,4,3,,124963825,3510,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
178,540210,4,3,,124963825,3510,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
179,540211,2,5,,124963825,3510,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
180,540212,4,3,,124963825,3510,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
181,540213,4,3,,124963825,3510,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
182,540256,1,2,,90340785,3510,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
183,540276,1,2,,90340785,3510,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
184,552110,2,10,,124963825,3510,Unspecified,1168222.0,3359.0,,,Partial agonist activity at human 5HT3A receptor expressed in HEK293 cells at 3 uM relative to 5HT,Other,21146988.0,
185,552297,2,10,,124963825,3510,Unspecified,1168222.0,3359.0,,,Partial agonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as decrease in 100 uM 5-chloroindole-induced increase in intracellular calcium release at 3 uM relative to 5-HT,Other,21146988.0,
186,576612,7,5,,124963825,3510,Active,7531135.0,3757.0,3.80189,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
187,588214,2,3,,124963825,3510,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
188,588215,2,3,,124963825,3510,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
189,588216,2,3,,124963825,3510,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
190,588217,2,3,,124963825,3510,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
191,588218,2,3,,124963825,3510,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
192,588219,2,3,,124963825,3510,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
193,588349,1,1,,90340785,3510,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
194,588378,1,1,,90340785,3510,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
195,588453,1,1,,90340785,3510,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
196,588456,1,1,,90340785,3510,Inactive,8659577.0,58819.0,35.4813,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
197,588579,1,1,,90340785,3510,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
198,588795,1,1,,90340785,3510,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
199,589039,1,10,,124963825,3510,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
200,602332,1,1,,90340785,3510,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
201,624146,1,1,,90340785,3510,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
202,624147,1,1,,90340785,3510,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
203,624148,1,2,,90340785,3510,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
204,624149,1,1,,90340785,3510,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
205,624455,1,1,,90340785,3510,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
206,625144,5,5,,124963825,3510,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
207,625145,4,7,,124963825,3510,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
208,625146,5,5,,124963825,3510,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
209,625147,4,7,,124963825,3510,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
210,625148,4,7,,124963825,3510,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
211,625149,4,7,,124963825,3510,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
212,625150,5,5,,124963825,3510,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
213,625151,4,7,,124963825,3510,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
214,625152,4,7,,124963825,3510,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
215,625153,4,7,,124963825,3510,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
216,625154,4,7,,124963825,3510,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
217,625155,4,7,,124963825,3510,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
218,625156,1,9,,124963825,3510,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
219,625157,6,2,,124963825,3510,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
220,625158,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
221,625159,5,5,,124963825,3510,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
222,625160,1,9,,124963825,3510,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
223,625161,4,7,,124963825,3510,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
224,625162,4,7,,124963825,3510,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
225,625163,4,7,,124963825,3510,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
226,625164,1,6,,124963825,3510,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
227,625165,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
228,625166,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
229,625167,5,5,,124963825,3510,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
230,625168,4,7,,124963825,3510,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
231,625169,1,6,,124963825,3510,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
232,625170,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
233,625171,4,7,,124963825,3510,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
234,625172,4,7,,124963825,3510,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
235,625173,5,5,,124963825,3510,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
236,625174,5,5,,124963825,3510,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
237,625175,5,5,,124963825,3510,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
238,625176,1,9,,124963825,3510,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
239,625177,5,5,,124963825,3510,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
240,625178,5,5,,124963825,3510,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
241,625179,1,9,,124963825,3510,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
242,625180,5,5,,124963825,3510,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
243,625181,5,5,,124963825,3510,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
244,625182,5,5,,124963825,3510,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
245,625183,5,5,,124963825,3510,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
246,625184,5,5,,124963825,3510,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
247,625185,5,5,,124963825,3510,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
248,625186,5,5,,124963825,3510,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
249,625187,5,5,,124963825,3510,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
250,625188,1,9,,124963825,3510,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
251,625189,1,7,,124963825,3510,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
252,625190,4,5,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
253,625191,4,7,,124963825,3510,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
254,625192,4,7,,124963825,3510,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
255,625193,5,5,,124963825,3510,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
256,625194,4,7,,124963825,3510,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
257,625195,4,7,,124963825,3510,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
258,625196,5,6,,124963825,3510,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
259,625197,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
260,625198,4,7,,124963825,3510,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
261,625199,4,7,,124963825,3510,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
262,625200,4,7,,124963825,3510,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
263,625201,4,7,,124963825,3510,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
264,625202,4,7,,124963825,3510,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
265,625203,4,7,,124963825,3510,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
266,625204,4,7,,124963825,3510,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
267,625205,4,7,,124963825,3510,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
268,625206,4,7,,124963825,3510,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
269,625207,4,7,,124963825,3510,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
270,625208,5,5,,124963825,3510,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
271,625209,4,7,,124963825,3510,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
272,625210,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
273,625211,1,6,,124963825,3510,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
274,625212,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
275,625213,4,7,,124963825,3510,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
276,625214,1,9,,124963825,3510,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
277,625215,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
278,625216,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
279,625217,4,7,,124963825,3510,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
280,625218,4,7,,124963825,3510,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
281,625219,3,4,,124963825,3510,Active,,,0.00339,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
282,625220,4,7,,124963825,3510,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
283,625221,4,7,,124963825,3510,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
284,625222,4,7,,124963825,3510,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
285,625223,4,7,,124963825,3510,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
286,625224,3,4,,124963825,3510,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
287,625225,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
288,625226,4,7,,124963825,3510,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
289,625227,4,7,,124963825,3510,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
290,625228,4,7,,124963825,3510,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
291,625229,5,5,,124963825,3510,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
292,625230,1,6,,124963825,3510,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
293,625231,4,7,,124963825,3510,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
294,625232,1,9,,124963825,3510,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
295,625233,4,7,,124963825,3510,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
296,625234,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
297,625235,4,7,,124963825,3510,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
298,625236,5,5,,124963825,3510,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
299,625237,4,7,,124963825,3510,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
300,625238,4,7,,124963825,3510,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
301,625239,4,7,,124963825,3510,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
302,625240,1,9,,124963825,3510,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
303,625241,4,7,,124963825,3510,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
304,625242,4,7,,124963825,3510,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
305,625243,5,5,,124963825,3510,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
306,625244,5,5,,124963825,3510,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
307,625245,5,5,,124963825,3510,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
308,625246,1,9,,124963825,3510,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
309,625247,5,5,,124963825,3510,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
310,625248,5,5,,124963825,3510,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
311,625249,5,5,,124963825,3510,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
312,625250,5,5,,124963825,3510,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
313,625251,5,5,,124963825,3510,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
314,625252,4,7,,124963825,3510,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
315,625253,4,7,,124963825,3510,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
316,625254,4,7,,124963825,3510,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
317,625255,4,7,,124963825,3510,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
318,625256,4,7,,124963825,3510,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
319,625257,4,7,,124963825,3510,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
320,625258,4,7,,124963825,3510,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
321,625259,4,7,,124963825,3510,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
322,625260,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
323,625261,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
324,625262,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
325,625263,4,7,,124963825,3510,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
326,625264,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
327,625265,1,6,,124963825,3510,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
328,625266,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
329,625267,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
330,625268,4,2,,124963825,3510,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
331,625268,4,2,,124963825,3510,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
332,625268,4,2,,124963825,3510,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
333,625268,4,2,,124963825,3510,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
334,625269,4,7,,124963825,3510,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
335,625270,4,7,,124963825,3510,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
336,625271,5,5,,124963825,3510,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
337,625272,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
338,625273,4,6,,124963825,3510,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
339,625274,1,6,,124963825,3510,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
340,625275,3,4,,124963825,3510,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
341,625279,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
342,625280,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
343,625281,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
344,625282,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
345,625283,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
346,625284,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
347,625285,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
348,625286,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
349,625287,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
350,625288,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
351,625289,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
352,625290,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
353,625291,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
354,625292,1,3,,124963825,3510,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
355,643471,4,6,,124963825,3510,Active,1168222.0,3359.0,0.00145,Ki,Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting,Confirmatory,22189135.0,
356,651635,1,3,,90340785,3510,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
357,652106,1,1,,90340785,3510,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
358,720538,1,2,,90340785,3510,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
359,720559,1,2,,90340785,3510,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
360,720572,1,2,,90340785,3510,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
361,720573,1,2,,90340785,3510,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
362,721751,2,5,,124963825,3510,Active,313104182.0,6582.0,4.3,IC50,Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
363,721752,2,5,,124963825,3510,Unspecified,74727585.0,146802.0,311.0,IC50,Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
364,721753,1,6,,124963825,3510,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
365,721754,2,5,,124963825,3510,Active,74731723.0,55244.0,5.0,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
366,742831,2,2,,124963825,3510,Active,1168222.0,3359.0,,,Serotonin 3a (5-HT3a) receptor antagonist,Other,,
367,743205,1,1,,90340785,3510,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
368,743205,1,1,,90340785,3510,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
369,743206,1,1,,90340785,3510,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
370,743206,1,1,,90340785,3510,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
371,743207,1,1,,90340785,3510,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
372,743207,1,1,,90340785,3510,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
373,743244,1,1,,90340785,3510,Inconclusive,,,6.3096,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
374,943390,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020205,Other,,
375,943391,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020205,Other,,
376,943392,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020205,Other,,
377,943393,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020205,Other,,
378,943394,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020205,Other,,
379,943395,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020205,Other,,
380,943396,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020205,Other,,
381,943397,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020205,Other,,
382,943398,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020205,Other,,
383,943399,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020205",Other,,
384,943400,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020205,Other,,
385,943401,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020205,Other,,
386,943402,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020205,Other,,
387,943403,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020205,Other,,
388,945424,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020205,Other,,
389,945425,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020205,Other,,
390,945426,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020205,Other,,
391,945427,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020205,Other,,
392,945428,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020205,Other,,
393,945429,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020205,Other,,
394,945430,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020205",Other,,
395,945431,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020205,Other,,
396,945432,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020205,Other,,
397,946063,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020205,Other,,
398,946064,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020205,Other,,
399,946065,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020205,Other,,
400,946066,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020205,Other,,
401,946067,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020205,Other,,
402,946068,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020205,Other,,
403,946069,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020205,Other,,
404,946070,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020205,Other,,
405,946071,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020205,Other,,
406,946072,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020205,Other,,
407,946073,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020205,Other,,
408,946074,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020205,Other,,
409,946075,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020205,Other,,
410,946076,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020205,Other,,
411,946077,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020205,Other,,
412,953004,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020205,Other,,
413,953005,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020205,Other,,
414,953006,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020205,Other,,
415,953007,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020205,Other,,
416,953008,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020205,Other,,
417,953009,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020205,Other,,
418,953010,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020205,Other,,
419,953641,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020205,Other,,
420,953642,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020205,Other,,
421,953643,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020205,Other,,
422,953644,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020205,Other,,
423,953645,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020205,Other,,
424,953646,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020205,Other,,
425,953647,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020205,Other,,
426,953648,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020205,Other,,
427,953649,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020205,Other,,
428,953650,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020205,Other,,
429,953651,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020205,Other,,
430,953652,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020205,Other,,
431,953653,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020205,Other,,
432,953654,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020205,Other,,
433,953655,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020205,Other,,
434,953656,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020205,Other,,
435,953657,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020205,Other,,
436,953658,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020205,Other,,
437,953659,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020205,Other,,
438,953660,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020205,Other,,
439,953661,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020205,Other,,
440,953662,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020205,Other,,
441,953663,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020205,Other,,
442,953664,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020205,Other,,
443,953665,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020205,Other,,
444,953666,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020205,Other,,
445,953667,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020205,Other,,
446,953668,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020205,Other,,
447,953669,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020205,Other,,
448,953670,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020205,Other,,
449,953671,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020205,Other,,
450,996610,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020205",Other,,
451,996611,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020205,Other,,
452,996612,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020205",Other,,
453,996613,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020205,Other,,
454,996614,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020205",Other,,
455,996615,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
456,996616,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020205",Other,,
457,996617,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020205",Other,,
458,996618,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
459,996619,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020205",Other,,
460,996620,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020205",Other,,
461,996621,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
462,996622,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
463,996623,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020205",Other,,
464,996624,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020205,Other,,
465,996625,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
466,996626,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020205",Other,,
467,996627,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
468,996628,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
469,996629,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
470,996630,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
471,996631,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020205",Other,,
472,996632,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
473,996633,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
474,997217,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020205",Other,,
475,997218,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
476,997219,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020205",Other,,
477,997220,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020205",Other,,
478,997221,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020205",Other,,
479,997222,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020205,Other,,
480,997223,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020205,Other,,
481,997224,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020205",Other,,
482,997225,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
483,997226,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020205",Other,,
484,997227,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020205",Other,,
485,997228,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020205",Other,,
486,997229,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020205",Other,,
487,997230,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020205",Other,,
488,997231,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020205,Other,,
489,997232,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020205",Other,,
490,999091,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
491,999092,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
492,999093,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
493,999094,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020205",Other,,
494,999095,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020205,Other,,
495,999096,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
496,999097,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020205",Other,,
497,999098,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020205",Other,,
498,999099,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020205",Other,,
499,999100,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020205",Other,,
500,999101,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
501,999102,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020205",Other,,
502,999103,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020205",Other,,
503,999104,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020205",Other,,
504,999105,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020205",Other,,
505,999106,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020205",Other,,
506,999107,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020205",Other,,
507,999108,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020205",Other,,
508,999109,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020205",Other,,
509,999110,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020205,Other,,
510,999111,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
511,999692,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020205",Other,,
512,999693,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020205",Other,,
513,999694,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020205",Other,,
514,999695,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020205",Other,,
515,999696,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020205,Other,,
516,999697,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020205",Other,,
517,999698,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020205",Other,,
518,999699,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
519,999700,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
520,999701,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
521,999702,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020205",Other,,
522,999703,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020205",Other,,
523,1004616,1,3,,124963825,3510,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020205,Other,,
524,1004617,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
525,1004618,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020205",Other,,
526,1004619,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020205",Other,,
527,1004620,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020205",Other,,
528,1004621,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
529,1004622,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
530,1004623,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
531,1004624,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020205",Other,,
532,1004625,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020205",Other,,
533,1004626,1,3,,124963825,3510,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020205",Other,,
534,1056953,1,2,,124963825,3510,Active,,,2.3,EC50,Agonist activity at human 5-HT3B receptor I183A mutant by FLIPR assay,Confirmatory,24128813.0,
535,1056954,1,2,,124963825,3510,Active,,,2.6,EC50,Agonist activity at human 5-HT3B receptor E170A mutant by FLIPR assay,Confirmatory,24128813.0,
536,1056955,1,2,,124963825,3510,Active,,,3.2,EC50,Agonist activity at human 5-HT3B receptor Y143A mutant by FLIPR assay,Confirmatory,24128813.0,
537,1056956,1,2,,124963825,3510,Active,,,2.4,EC50,Agonist activity at human 5-HT3B receptor F130A mutant by FLIPR assay,Confirmatory,24128813.0,
538,1056957,1,2,,124963825,3510,Active,,,0.13,EC50,Agonist activity at human 5-HT3B receptor W90C mutant by FLIPR assay,Confirmatory,24128813.0,
539,1056958,1,2,,124963825,3510,Active,,,0.64,EC50,Agonist activity at human 5-HT3B receptor H73A mutant by FLIPR assay,Confirmatory,24128813.0,
540,1056959,2,3,,124963825,3510,Active,1168222.0,3359.0,0.5,EC50,Agonist activity at human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells by FLIPR assay,Confirmatory,24128813.0,
541,1056959,2,3,,124963825,3510,Active,74705987.0,9177.0,0.5,EC50,Agonist activity at human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells by FLIPR assay,Confirmatory,24128813.0,
542,1056960,1,1,,124963825,3510,Inactive,,,,,Agonist activity at human 5-HT3A receptor W183C mutant by FLIPR assay,Other,24128813.0,
543,1056961,1,2,,124963825,3510,Active,,,0.19,EC50,Agonist activity at human 5-HT3A receptor D165K mutant by FLIPR assay,Confirmatory,24128813.0,
544,1056962,1,2,,124963825,3510,Active,,,0.19,EC50,Agonist activity at human 5-HT3A receptor D165A mutant by FLIPR assay,Confirmatory,24128813.0,
545,1056963,1,2,,124963825,3510,Active,,,0.094,EC50,Agonist activity at human 5-HT3A receptor S163T mutant by FLIPR assay,Confirmatory,24128813.0,
546,1056964,1,2,,124963825,3510,Active,,,0.16,EC50,Agonist activity at human 5-HT3A receptor S163A mutant by FLIPR assay,Confirmatory,24128813.0,
547,1056965,1,1,,124963825,3510,Inactive,,,,,Agonist activity at human 5-HT3A receptor F130Y mutant by FLIPR assay,Other,24128813.0,
548,1056966,1,2,,124963825,3510,Active,,,0.13,EC50,Agonist activity at human 5-HT3A receptor F130A mutant by FLIPR assay,Confirmatory,24128813.0,
549,1056967,1,1,,124963825,3510,Inactive,,,,,Agonist activity at human 5-HT3A receptor W90C mutant by FLIPR assay,Other,24128813.0,
550,1056968,1,2,,124963825,3510,Active,,,0.07400000000000001,EC50,Agonist activity at human 5-HT3A receptor Y73S mutant by FLIPR assay,Confirmatory,24128813.0,
551,1056969,1,2,,124963825,3510,Active,,,0.45,EC50,Agonist activity at human 5-HT3A receptor Y73F mutant by FLIPR assay,Confirmatory,24128813.0,
552,1056970,2,3,,124963825,3510,Active,1168222.0,3359.0,0.32,EC50,Agonist activity at human wild type 5-HT3A receptor expressed in HEK293 cells by FLIPR assay,Confirmatory,24128813.0,
553,1056971,1,2,,124963825,3510,Active,,,0.08800000000000001,EC50,Agonist activity at human 5-HT3A receptor Y73A mutant by FLIPR assay,Confirmatory,24128813.0,
554,1056972,1,1,,124963825,3510,Unspecified,,,,,Ratio of Kd for human 5-HT3B receptor F130A mutant to Kd for human wild type 5-HT3A/5-HT3B receptor,Other,24128813.0,
555,1056973,1,1,,124963825,3510,Active,,,0.00011,Kd,Binding affinity to human 5-HT3B receptor E170A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
556,1056974,1,1,,124963825,3510,Active,,,0.0002,Kd,Binding affinity to human 5-HT3B receptor Y143A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
557,1056975,1,1,,124963825,3510,Active,,,0.00078,Kd,Binding affinity to human 5-HT3B receptor F130A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
558,1056976,1,1,,124963825,3510,Active,,,0.00025,Kd,Binding affinity to human 5-HT3B receptor W90C mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
559,1056977,1,1,,124963825,3510,Active,,,0.00022,Kd,Binding affinity to human 5-HT3B receptor H73A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
560,1056978,2,3,,124963825,3510,Active,1168222.0,3359.0,0.0002,Kd,Binding affinity to human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
561,1056978,2,3,,124963825,3510,Active,74705987.0,9177.0,0.0002,Kd,Binding affinity to human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
562,1056979,1,1,,124963825,3510,Inactive,,,,,Binding affinity to human 5-HT3A receptor W183C mutant after 24 hrs by liquid scintillation counting analysis,Other,24128813.0,
563,1056980,1,1,,124963825,3510,Active,,,0.00044,Kd,Binding affinity to human 5-HT3A receptor D165K mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
564,1056981,1,1,,124963825,3510,Active,,,0.00037,Kd,Binding affinity to human 5-HT3A receptor D165A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
565,1056982,1,1,,124963825,3510,Active,,,0.00018999999999999998,Kd,Binding affinity to human 5-HT3A receptor S163T mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
566,1056983,1,1,,124963825,3510,Active,,,0.00036,Kd,Binding affinity to human 5-HT3A receptor S163A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
567,1056984,1,1,,124963825,3510,Active,,,0.00049,Kd,Binding affinity to human 5-HT3A receptor F130Y mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
568,1056985,1,1,,124963825,3510,Active,,,0.00078,Kd,Binding affinity to human 5-HT3A receptor F130A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
569,1056986,1,1,,124963825,3510,Inactive,,,,,Binding affinity to human 5-HT3A receptor W90C mutant after 24 hrs by liquid scintillation counting analysis,Other,24128813.0,
570,1056987,1,1,,124963825,3510,Active,,,0.00041,Kd,Binding affinity to human 5-HT3A receptor Y73S mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
571,1056988,1,1,,124963825,3510,Active,,,0.0009,Kd,Binding affinity to human 5-HT3A receptor Y73F mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
572,1056989,1,1,,124963825,3510,Active,,,0.0006,Kd,Binding affinity to human 5-HT3A receptor Y73A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
573,1056990,1,1,,124963825,3510,Active,,,0.00016,Kd,Binding affinity to human 5-HT3B receptor I183A mutant after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
574,1056991,2,3,,124963825,3510,Active,1168222.0,3359.0,0.00053,Kd,Binding affinity to human wild type 5-HT3A receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis,Confirmatory,24128813.0,
575,1079931,1,1,,124963825,3510,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
576,1079932,1,1,,124963825,3510,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
577,1079933,1,1,,124963825,3510,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
578,1079934,1,1,,124963825,3510,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
579,1079935,1,1,,124963825,3510,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
580,1079936,1,1,,124963825,3510,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
581,1079937,1,1,,124963825,3510,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
582,1079938,1,1,,124963825,3510,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
583,1079939,1,1,,124963825,3510,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
584,1079940,1,1,,124963825,3510,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
585,1079941,1,1,,124963825,3510,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
586,1079942,1,1,,124963825,3510,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
587,1079943,1,1,,124963825,3510,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
588,1079944,1,1,,124963825,3510,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
589,1079945,1,1,,124963825,3510,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
590,1079946,1,1,,124963825,3510,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
591,1079947,1,1,,124963825,3510,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
592,1079948,1,1,,124963825,3510,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
593,1079949,1,1,,124963825,3510,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
594,1159620,1,1,,124963825,3510,Active,,,,,Summary of drug indications.,Other,,
595,1222793,1,1,,124963825,3510,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
596,1224859,2,1,,90340785,3510,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
597,1224863,1,1,,176484895,3510,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
598,1224863,1,1,,316920221,3510,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
599,1259416,1,2,,340079995,3510,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
600,1259421,1,1,,340079995,3510,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
601,1259423,1,2,,354935141,3510,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
